{"id":"ba3021","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5095285","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BA3021 works by inhibiting the PI3K enzyme, which is involved in cell signaling pathways that regulate cell growth and survival. This inhibition can lead to the death of cancer cells. By targeting the PI3K pathway, BA3021 aims to prevent cancer cell growth and proliferation.","oneSentence":"BA3021 is a small molecule targeting the PI3K pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:45.705Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT04918186","phase":"PHASE2","title":"Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2022-05-03","conditions":"Ovarian Cancer","enrollment":60},{"nctId":"NCT05271604","phase":"PHASE2","title":"A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2022-12-13","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck","enrollment":42},{"nctId":"NCT03504488","phase":"PHASE1, PHASE2","title":"CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2018-06-27","conditions":"Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BA3021","genericName":"BA3021","companyName":"Canadian Cancer Trials Group","companyId":"canadian-cancer-trials-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BA3021 is a small molecule targeting the PI3K pathway. Used for Relapsed or refractory acute myeloid leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}